Cargando…

Homocysteine, B vitamins, and cardiovascular disease: a Mendelian randomization study

BACKGROUND: Whether a modestly elevated homocysteine level is causally associated with an increased risk of cardiovascular disease remains unestablished. We conducted a Mendelian randomization study to assess the associations of circulating total homocysteine (tHcy) and B vitamin levels with cardiov...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Shuai, Mason, Amy M., Carter, Paul, Burgess, Stephen, Larsson, Susanna C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8063383/
https://www.ncbi.nlm.nih.gov/pubmed/33888102
http://dx.doi.org/10.1186/s12916-021-01977-8
_version_ 1783681943500488704
author Yuan, Shuai
Mason, Amy M.
Carter, Paul
Burgess, Stephen
Larsson, Susanna C.
author_facet Yuan, Shuai
Mason, Amy M.
Carter, Paul
Burgess, Stephen
Larsson, Susanna C.
author_sort Yuan, Shuai
collection PubMed
description BACKGROUND: Whether a modestly elevated homocysteine level is causally associated with an increased risk of cardiovascular disease remains unestablished. We conducted a Mendelian randomization study to assess the associations of circulating total homocysteine (tHcy) and B vitamin levels with cardiovascular diseases in the general population. METHODS: Independent single nucleotide polymorphisms associated with tHcy (n = 14), folate (n = 2), vitamin B6 (n = 1), and vitamin B12 (n = 14) at the genome-wide significance level were selected as instrumental variables. Summary-level data for 12 cardiovascular endpoints were obtained from genetic consortia, the UK Biobank study, and the FinnGen consortium. RESULTS: Higher genetically predicted circulating tHcy levels were associated with an increased risk of stroke. For each one standard deviation (SD) increase in genetically predicted tHcy levels, the odds ratio (OR) was 1.11 (95% confidence interval (CI), 1.03, 1.21; p = 0.008) for any stroke, 1.26 (95% CI, 1.05, 1.51; p = 0.013) for subarachnoid hemorrhage, and 1.11 (95% CI, 1.03, 1.21; p = 0.011) for ischemic stroke. Higher genetically predicted folate levels were associated with decreased risk of coronary artery disease (OR(SD), 0.88; 95% CI, 0.78, 1.00, p = 0.049) and any stroke (OR(SD), 0.86; 95% CI, 0.76, 0.97, p = 0.012). Genetically predicted increased vitamin B6 levels were associated with a reduced risk of ischemic stroke (OR(SD), 0.88; 95% CI, 0.81, 0.97, p = 0.009). None of these associations persisted after multiple testing correction. There was no association between genetically predicted vitamin B12 and cardiovascular disease. CONCLUSIONS: This study reveals suggestive evidence that B vitamin therapy and lowering of tHcy may reduce the risk of stroke, particularly subarachnoid hemorrhage and ischemic stroke. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12916-021-01977-8.
format Online
Article
Text
id pubmed-8063383
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-80633832021-04-23 Homocysteine, B vitamins, and cardiovascular disease: a Mendelian randomization study Yuan, Shuai Mason, Amy M. Carter, Paul Burgess, Stephen Larsson, Susanna C. BMC Med Research Article BACKGROUND: Whether a modestly elevated homocysteine level is causally associated with an increased risk of cardiovascular disease remains unestablished. We conducted a Mendelian randomization study to assess the associations of circulating total homocysteine (tHcy) and B vitamin levels with cardiovascular diseases in the general population. METHODS: Independent single nucleotide polymorphisms associated with tHcy (n = 14), folate (n = 2), vitamin B6 (n = 1), and vitamin B12 (n = 14) at the genome-wide significance level were selected as instrumental variables. Summary-level data for 12 cardiovascular endpoints were obtained from genetic consortia, the UK Biobank study, and the FinnGen consortium. RESULTS: Higher genetically predicted circulating tHcy levels were associated with an increased risk of stroke. For each one standard deviation (SD) increase in genetically predicted tHcy levels, the odds ratio (OR) was 1.11 (95% confidence interval (CI), 1.03, 1.21; p = 0.008) for any stroke, 1.26 (95% CI, 1.05, 1.51; p = 0.013) for subarachnoid hemorrhage, and 1.11 (95% CI, 1.03, 1.21; p = 0.011) for ischemic stroke. Higher genetically predicted folate levels were associated with decreased risk of coronary artery disease (OR(SD), 0.88; 95% CI, 0.78, 1.00, p = 0.049) and any stroke (OR(SD), 0.86; 95% CI, 0.76, 0.97, p = 0.012). Genetically predicted increased vitamin B6 levels were associated with a reduced risk of ischemic stroke (OR(SD), 0.88; 95% CI, 0.81, 0.97, p = 0.009). None of these associations persisted after multiple testing correction. There was no association between genetically predicted vitamin B12 and cardiovascular disease. CONCLUSIONS: This study reveals suggestive evidence that B vitamin therapy and lowering of tHcy may reduce the risk of stroke, particularly subarachnoid hemorrhage and ischemic stroke. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12916-021-01977-8. BioMed Central 2021-04-23 /pmc/articles/PMC8063383/ /pubmed/33888102 http://dx.doi.org/10.1186/s12916-021-01977-8 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Yuan, Shuai
Mason, Amy M.
Carter, Paul
Burgess, Stephen
Larsson, Susanna C.
Homocysteine, B vitamins, and cardiovascular disease: a Mendelian randomization study
title Homocysteine, B vitamins, and cardiovascular disease: a Mendelian randomization study
title_full Homocysteine, B vitamins, and cardiovascular disease: a Mendelian randomization study
title_fullStr Homocysteine, B vitamins, and cardiovascular disease: a Mendelian randomization study
title_full_unstemmed Homocysteine, B vitamins, and cardiovascular disease: a Mendelian randomization study
title_short Homocysteine, B vitamins, and cardiovascular disease: a Mendelian randomization study
title_sort homocysteine, b vitamins, and cardiovascular disease: a mendelian randomization study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8063383/
https://www.ncbi.nlm.nih.gov/pubmed/33888102
http://dx.doi.org/10.1186/s12916-021-01977-8
work_keys_str_mv AT yuanshuai homocysteinebvitaminsandcardiovasculardiseaseamendelianrandomizationstudy
AT masonamym homocysteinebvitaminsandcardiovasculardiseaseamendelianrandomizationstudy
AT carterpaul homocysteinebvitaminsandcardiovasculardiseaseamendelianrandomizationstudy
AT burgessstephen homocysteinebvitaminsandcardiovasculardiseaseamendelianrandomizationstudy
AT larssonsusannac homocysteinebvitaminsandcardiovasculardiseaseamendelianrandomizationstudy